Isogenica Limited

Isogenica Ltd from Saffron Walden UK: a small, active company founded 27 years ago, employs 16 people, and holds £1,123,249 in assets. It has a real address, four directors, and two owners. The company regularly imports miscellaneous chemical products, with activity recorded for the last four months.

The company specializes in the discovery and engineering of small format, singledomain antibodies VHH, offering exceptional robustness, flexibility, and scalability across varied therapeutic and diagnostic applications. Combining its synthetic VHH libraries with proprietary cell-free CIS display technology, Isogenica aims to accelerate antibody discovery. Its website highlights tools for ADC drug discovery, screening, and applications, showcasing a focus on biotechnology research and development. They also collaborate with other companies, like Cube Biotech, to tackle challenges in drug discovery, particularly with GPCRs. The company's team is committed to pushing the boundaries of antibody research, and they invite visitors to connect at industry events like PEGS in Boston.

Financially, Isogenica Ltd’s report shows some interesting trends. While its total assets remain stable, cash reserves decreased by 34% to £340,000. Creditors increased significantly by 42%, and trade debtors rose by 65%, suggesting a need to manage cash flow. Net assets, however, remained stable. The company’s small size—meeting two of three criteria for a small company—helps it stay agile, but the increased debt could be a concern. The company’s bank borrowings increased by 100%, which is a notable change. The report doesn’t mention an auditor, which is common for small companies. Development costs capitalised have increased, which could mean the company is investing in its future.

Registered in England/Wales under the registration number 03571781, with a registered address at CB10 1XL, Saffron Walden, Essex, The Mansion Chesterford Research Park, Little Chesterford.

WARNING:The numbers have been rounded for simplicity and may be inaccurate.Please, refer to the latest financial report for verification.